HVTN 104 CONSORT flow diagram (A) and specimen collection schedule (B).
- Kenneth H. Mayer (116219)
- Kelly E. Seaton (603000)
- Yunda Huang (235282)
- Nicole Grunenberg (662181)
- Abby Isaacs (4591450)
- Mary Allen (742378)
- Julie E. Ledgerwood (253787)
- Ian Frank (10438)
- Magdalena E. Sobieszczyk (332353)
- Lindsey R. Baden (189735)
- Benigno Rodriguez (89118)
- Hong Van Tieu (2190166)
- Georgia D. Tomaras (164058)
- Aaron Deal (4591447)
- Derrick Goodman (4591453)
- Robert T. Bailer (241545)
- Guido Ferrari (164054)
- Ryan Jensen (2806675)
- John Hural (173295)
- Barney S. Graham (194312)
- John R. Mascola (229761)
- Lawrence Corey (140058)
- David C. Montefiori (108747)
Publication date
November 2017
DOIAbstract
<p>T1: 20 mg/kg IV q 4 weeks with 40 mg/kg IV loading; T2: 40 mg/kg IV q 8 weeks; T3 (P3): 5 mg/kg SC q 2 weeks with 40 mg/kg IV loading; T4: 10 mg/kg IV q 8 weeks; T5: 30 mg/kg IV q 8 weeks. ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; CONSORT, Consolidated Standards of Reporting Trials; HVTN, HIV Vaccine Trials Network; IV, intravenous; P3, placebo group 3; q, quodque; SC, subcutaneous; T1, treatment group 1; T2, treatment group 2; T3, treatment group 3; T4, treatment group 4; T5, treatment group 5.</p
Add to ORKG